AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sorbitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2462 | 50-70-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. It is also used in many manufacturing processes, as a pharmaceutical aid, and in several research applications.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 2350 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.500 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.309 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.560 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 0.692 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 90.970 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 96.530 | % | High | 1 |
| herg | hERG pIC50 | 3.502 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 0.914 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.221 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 85.930 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK | 34 | |||
| kinase-selectivity-class | ACVRL1,AURKB,AXL,BMX,BRAF,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,EPHB4,IGF1R,INSR,IRAK1,IRAK3,IRAK4,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,PAK4,PDGFRB,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SYK,TEK,TGFBR1,TYRO3,ZAP70 | 39 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.269 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 0.182 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 97.890 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.316 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 96.500 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.671 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 96.880 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 96.890 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 950.605 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 20, 1971 | FDA | HOSPIRA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Transurethral resection syndrome | 42.10 | 28.11 | 5 | 506 | 29 | 42620795 |
| Biopsy rectum abnormal | 28.92 | 28.11 | 3 | 508 | 3 | 42620821 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Crystal deposit intestine | 50.18 | 25.46 | 7 | 797 | 267 | 110588228 |
| Biopsy rectum abnormal | 40.56 | 25.46 | 4 | 800 | 4 | 110588491 |
| Rectal ulcer | 34.54 | 25.46 | 7 | 797 | 2560 | 110585935 |
| Excessive granulation tissue | 33.79 | 25.46 | 6 | 798 | 1088 | 110587407 |
| Gastrointestinal necrosis | 32.97 | 25.46 | 8 | 796 | 6632 | 110581863 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A06AD18 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Osmotically acting laxatives |
| ATC | A06AG07 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Enemas |
| ATC | B05CX02 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Other irrigating solutions |
| ATC | V04CC01 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for bile duct patency |
| MeSH PA | D002400 | Cathartics |
| MeSH PA | D005421 | Flavoring Agents |
| MeSH PA | D005503 | Food Additives |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D007202 | Indicators and Reagents |
| MeSH PA | D013549 | Sweetening Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50503 | laxative |
| CHEBI has role | CHEBI:50505 | sweetening agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75325 | cathartic |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:77969 | food humectant |
Related Drugs by ATC class:
A06AD Osmotically acting laxatives 13 drugs
A06AG Enemas 5 drugs
V04CC Tests for bile duct patency 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Unknown Oral Substance Toxicity | indication | ||
| Bowel sounds absent | contraindication | 16268000 | |
| Hypovolemia | contraindication | 28560003 | |
| Gastrointestinal perforation | contraindication | 51875005 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Gastrointestinal obstruction | contraindication | 126765001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.21 | acidic |
| pKa2 | 13.75 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4017867 | VUID |
| N0000146220 | NUI |
| 4017867 | VANDF |
| C0037688 | UMLSCUI |
| CHEBI:30911 | CHEBI |
| SOR | PDB_CHEM_ID |
| CHEMBL1682 | ChEMBL_ID |
| DB01638 | DRUGBANK_ID |
| D013012 | MESH_DESCRIPTOR_UI |
| 5780 | PUBCHEM_CID |
| 506T60A25R | UNII |
| 9945 | RXNORM |
| 11078 | MMSL |
| 5502 | MMSL |
| d04159 | MMSL |
| 002599 | NDDF |
| 19839007 | SNOMEDCT_US |
| 412513004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Sorbitol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-0295 | IRRIGANT | 30 g | IRRIGATION | NDA | 15 sections |
| Sorbitol-Mannitol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0990-7981 | IRRIGANT | 2.70 g | URETHRAL | NDA | 12 sections |
| Sorbitol-Mannitol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0990-7981 | IRRIGANT | 2.70 g | URETHRAL | NDA | 12 sections |
| Sorbitol | HUMAN OTC DRUG LABEL | 1 | 52471-111 | SOLUTION | 1 g | RECTAL | OTC monograph not final | 8 sections |
| Sorbitol | HUMAN OTC DRUG LABEL | 1 | 54162-700 | SOLUTION | 258.20 g | ORAL | OTC monograph not final | 8 sections |
| GeriCare Sorbitol Solution | HUMAN OTC DRUG LABEL | 1 | 57896-758 | LIQUID | 70 mg | RECTAL | OTC Monograph Drug | 10 sections |
| Onsaemiro Damda | HUMAN OTC DRUG LABEL | 8 | 82341-302 | LIQUID | 0.30 g | TOPICAL | unapproved drug other | 11 sections |
| Anubis Barcelona | HUMAN OTC DRUG LABEL | 11 | 83021-877 | CONCENTRATE | 0.05 g | TOPICAL | OTC monograph final | 6 sections |
| Chebe Butter | HUMAN OTC DRUG LABEL | 2 | 84025-056 | CREAM | 3 mg | CUTANEOUS | OTC Monograph Drug | 6 sections |
| SUMIFANGToothpaste | HUMAN OTC DRUG LABEL | 2 | 84025-110 | CREAM | 5 mg | DENTAL | OTC Monograph Drug | 5 sections |
| Beard Wash Conditioner | HUMAN OTC DRUG LABEL | 2 | 84025-161 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Batana Oil | HUMAN OTC DRUG LABEL | 2 | 84025-172 | OIL | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Onion Biotin Conditioner | HUMAN OTC DRUG LABEL | 2 | 84025-174 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Biotin Jojoba HairConditioner | HUMAN OTC DRUG LABEL | 2 | 84025-176 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Rosemary OilShampoo And Conditioner Set | HUMAN OTC DRUG LABEL | 2 | 84025-201 | SHAMPOO | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| 100% Unrefined Batana Oil Hair Mask | HUMAN OTC DRUG LABEL | 2 | 84025-220 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Kojic Acid Turmeric Face and Body Scrub | HUMAN OTC DRUG LABEL | 2 | 84025-224 | CREAM | 7 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Batana Oil Hair Mask | HUMAN OTC DRUG LABEL | 2 | 84025-225 | CREAM | 6 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Kojic Acid Face and Body Scrub | HUMAN OTC DRUG LABEL | 2 | 84025-226 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Oil-Free Acne Wash | HUMAN OTC DRUG LABEL | 2 | 84025-233 | CREAM | 7 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| 100% Raw Batana Oil | HUMAN OTC DRUG LABEL | 2 | 84025-237 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Batana Oil | HUMAN OTC DRUG LABEL | 2 | 84025-238 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Turmeric Body Wash | HUMAN OTC DRUG LABEL | 2 | 84025-252 | CREAM | 15 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Vitamin C Aloe Vera Face and Body Scrub | HUMAN OTC DRUG LABEL | 2 | 84025-259 | CREAM | 5 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| cleansing exfoliating facewash | HUMAN OTC DRUG LABEL | 2 | 84025-261 | CREAM | 4 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Mint Aloe Men Care Body Wash | HUMAN OTC DRUG LABEL | 2 | 84025-262 | CREAM | 15 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| beard oil | HUMAN OTC DRUG LABEL | 2 | 84025-265 | LIQUID | 2 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Cooling Face Wash | HUMAN OTC DRUG LABEL | 2 | 84025-282 | CREAM | 4 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Men Care Body Wash | HUMAN OTC DRUG LABEL | 2 | 84025-296 | CREAM | 3 mg | CUTANEOUS | OTC Monograph Drug | 5 sections |
| Microlax Enema | HUMAN OTC DRUG LABEL | 1 | 84177-0020 | ENEMA | 625 mg | RECTAL | unapproved drug other | 8 sections |